Michael H. Kroll MDProfessor of Medicine and Chief, Section of Benign Hematology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dr. Michael Kroll is a hematologist and oncologist practicing in Houston, Texas. He is Professor of Medicine and Chief of the Section of Benign Hematology at the University of Texas MD Anderson Cancer Center (UTMDACC). His basic research background is in mechanisms of platelet-dependent thrombosis, and his academic clinical niche is benign hematology, hemostasis and thrombosis. His group’s research activities focus on mechanisms of cancer- and stem cell transplant–associated thrombotic microangiopathy, the prevention and treatment of venous thromboembolism in cancer patients, and mechanisms of cancer-induced venous thrombosis.
Dr. Kroll is intimately involved in fellowship training, co-directs UTMDACC’s Anticoagulant Stewardship Program, has published over 100 manuscripts in peer-reviewed journals, lectures world-wide over a dozen times per year, serves on 2 federal grant review committees, has received several awards for education and leadership, and has served The American Society of Hematology in various capacities.
Dr. Kroll received his medical degree from Cornell. He underwent residency training in internal medicine at Brown University and completed his fellowship in hematology/oncology at Harvard Medical School–Brigham & Women's Hospital.
Recent Contributions to PracticeUpdate:
- ASH 2018 Guidelines for Heparin-Induced Thrombocytopenia in Patients With VTE
- ASH 2018 Guidelines for the Management of VTE: Optimal Management of Anticoagulation Therapy
- 2018 Top Stories in Benign Hematology: Severe Thalassemias
- Acquired Platelet Antagonism: Off-Target Antiplatelet Effects of Malignancy Treatment With TKIs
- Improving Management of Iron Deficiency Anemia in the Emergency Department
- Age of Transfused Blood in Critically Ill Adult Trauma Patients
- Mechanisms of Platelet Clearance and Translation to Improve Platelet Storage
- A Surgeon’s Guide to DOACs
- Effectiveness and Safety of NOACs Compared With Phenprocoumon for Atrial Fibrillation
- Significant Differences in Progression Risk Between Patients With IgM MGUS and Non-IgM MGUS